A A resistência bacteriana à antimicrobianos na pandemia da covid-19

Bacterial resistance to antimicrobials the covid-19 pandemic

Authors

  • Alexsandra Correia Baumgartner Uniamérica Campus Biopark
  • Fernanda Kaefer UniAmérica
  • Dayane Kelly Sabec Pereira Uniamérica Campus Biopark

DOI:

https://doi.org/10.33362/ext.v11i1.3170

Keywords:

Antimicrobials. Bacterial resistance. COVID-19. Microorganisms

Abstract

Covid-19 affects the cells of the lower respiratory tract, which triggers an inflammatory cascade in the body. During these infections, it is up to the immune system to eliminate pathogens in order to recover cellular homeostasis and repair tissues. When there is a failure in this pathway, the immune system finds it difficult to regain balance, one of these problems can be caused by secondary infections, which generates additional clinical complications. Thus, this research aims to address aspects such as the prevalence and incidence of the main strains of bacteria found in patients hospitalized with covid-19 in a hospital in the western region of Paraná and to evaluate the prevalent pharmacotherapy used for the treatment of patients. The methodology of this study consists of a cross-sectional observational study with retrospective recruitment based on the collection of data from medical records of patients who were admitted to the Intensive Care Unit of a private hospital in Western Paraná between January and October 2021.

According to the results found, antibiograms were performed in more than 70% of patients hospitalized during the research period and the use of antimicrobials was carried out empirically, even in cases in which there was no identified bacterial growth. Ceftriaxone and azithromycin were the drugs most used individually and in associations.

Author Biography

Alexsandra Correia Baumgartner, Uniamérica Campus Biopark

Covid-19 affects the cells of the lower respiratory tract, which triggers an inflammatory cascade in the body. During these infections, it is up to the immune system to eliminate pathogens in order to recover cellular homeostasis and repair tissues. When there is a failure in this pathway, the immune system finds it difficult to regain balance, one of these problems can be caused by secondary infections, which generates additional clinical complications. Thus, this research aims to address aspects such as the prevalence and incidence of the main strains of bacteria found in patients hospitalized with covid-19 in a hospital in the western region of Paraná and to evaluate the prevalent pharmacotherapy used for the treatment of patients. The methodology of this study consists of a cross-sectional observational study with retrospective recruitment based on the collection of data from medical records of patients who were admitted to the Intensive Care Unit of a private hospital in Western Paraná between January and October 2021.

According to the results found, antibiograms were performed in more than 70% of patients hospitalized during the research period and the use of antimicrobials was carried out empirically, even in cases in which there was no identified bacterial growth. Ceftriaxone and azithromycin were the drugs most used individually and in associations.

References

ALVES, Rafaela Pereiraet al. Perfil dos pacientes adultos com COVID-19 internados em uma unidade de terapia intensiva. Pesquisa, Sociedade e Desenvolvimento , v. 11, n. 5, pág. e43411528481-e43411528481, 2022.

ANVISA. PIPERACILINA+TAZOBACTAM.[Bula]. Cosmópolis:Abl Antibióticos do Brasil. Disponível em: https://consultas.anvisa.gov.br/#/bulario/q/?nomeProduto=PIPERACILINA%20S%C3%93DICA%2BTAZOBACTAM%20S%C3%93DICOAcesso em 17 de jun.2023.

AVELAR, F. G de; Emmerick, I. C. M.; Muzy, J.; CAMPOS, M. R..Complicações da Covid-19: desdobramentos para o Sistema Único de Saúde. Physis: Revista de Saúde Coletiva, Rio de Janeiro, v. 31(1), e310133, 2021. DOI: http://dx.doi.org/10.1590/S0103-73312021310133. Acesso: 10 maio 2022.BMC Infect Dis 21, 571.

BASSO ME, Pulcinellii RSR, Aquino ARC, Santos KF. Prevalência de infecções bacterianas em pacientes internados em uma unidade de terapia intensiva (UTI). Rev Bras Anal Clin. 2016;48(4): 383-88.

BJ Langford , M. So , S. Raybardhan , V. Leung , D. Westwood , DR MacFadden , et al..Coinfecção bacteriana e infecção secundária em pacientes com COVID-19: uma revisão rápida e metanálise.Clin MicrobiolInfect , 26 ( 2020 ) , pp . 1622-1629

CAMPOS, Francisco Carlos Cardoso de et al. O Brasil na UTI: atenção hospitalar em tempos de pandemia. Scielo, [S.L.], p. 1-22, 15 out. 2020. FapUNIFESP (SciELO). http://dx.doi.org/10.1590/scielopreprints.1368.

CDC. COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022. Atlanta, GA: U.S. Department of Health and Human Services, CDC, 2022.https://www.cdc.gov/drugresistance/covid19.html DOI: https://dx.doi.org/10.15620/cdc:117915

CENTRO DE SAÚDE DA COMUNIDADE (CECOM) UNICAMP. Informações úteis.

Disponível em: https://www.cecom.unicamp.br/informativo-cecom-16-04-2020-covid- 19/. Acesso em: 10 mai. 2022

CLANCY C. J., NGUYEN. M. H. Coronavirus Disease 2019, Superinfections, and Antimicrobial Development: What Can We Expect? Clin Infect Dis. V 71, n10. 2020. Doi: 10.1093/cid/ciaa524.

COX, M. J., LOMAN, N., BOGAERT, D., & O'GRADY, J. (2020). Co-infections:

potentially lethal and unexplored in COVID-19. The Lancet Microbe, 1(1), e11.

D’HUMIÈRES, C. et al. Two Original Observations Concerning Bacterial Infections in COVID-19 Patients Hospitalized in Intensive Care Units during the First Wave of the Epidemic in France. PloS one, v. 16, n. 4, p. e0250728, 29 abril 2022.

FEITOZA, T. M. O.; CHAVES, A. M.; MUNIZ, G. T. S.; CRUZ, M. C. C.; JUNIOR, I. F.

C. Comorbidades E COVID-19: Uma Revisão Integrativa. Revista Interfaces, v.8,n.3,p.711723,2020.Disponívelem: acessado em: 10 maio 2022.

FELDMAN C, ANDERSON R. The role of co-infections and secondary infections in patients with COVID-19. Pneumonia, 2021.

FREIRES, M. S.; JUNIOR, O. M. R. Resistência bacteriana pelo uso indiscriminado da azitromicina frente a Covid-19: uma revisão integrativa. Research, Society and Development, v. 11, n. 1, 2022. Disponível em: file:///C:/Users/clien/Downloads/Art.%20Resit.%20Bacter.%20Azitro.pdf> acessado em: 10 mai 2022.

GAUTRET, et al. (2020) Hydroxychloroquine and azitromycin as a treatmet of Covid 19: results of na open-label non-randomized clinical trial. Ed. 1,P. 105 949.

GORBALENYA AE et. al. Severe acute respiratory syndromerelated coronavirus: The species and its viroses: a statement of the Coronavirus Study Group. Disponível em: <https://doi.org/10.1101/2020.02.07.937862>. Acesso em: 03 mai 2022.

HANLON, P. et al. Covid-19 – exploring the implications of long-term condition type and extent of multimorbidity on years of life lost: a modelling study. Wellcome Open Research, v. 5, p. 75, 23 abr. 2020.

HUANG, C., WANG, Y., LI, X., REN, L., ZHAO, J., HU, Y. & CHENG, Z. (2020). Clinical

features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet, 395(10223), 497-506.

HUSSAR, Yasmin Leite. Perfil de Utilização de Antimicrobianos de uso restrito e resistência bacteriana durante a pandemia de Covid- 19 na UTI do Hospital Santa Casa da Misericórdia de Ouro Preto. Trabalho de Conslusão de Curso apresentado para obtenção de Bacharel em Farmácia. Universidade Federal de Ouro Pretp. Minas Gerais , 2022.

KALPOE, S., SONNENHBERG, E., FACTOR, S. H., MARTIN, J. R., PATEL, T. S. G.,

& HUPRIK, S. (2012). Mortality associated with carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients. Liver Transplantation, 18(4).

KLEIN, E. Y., MONTEFORTE, B., GUPTA, A., JIANG, W., MAY, L., HSIEH, Y. H., &

DUGAS, A. (2016). The frequency of influenza and bacterial coinfection: a systematic review and meta‐analysis. Influenza and other respiratory viruses, 10(5), 394-403.

LANSBURY, L., LIM, B., BASKARAN, V., & LIM, W. S. (2020). Co-infections in

people with COVID-19: a systematic review and meta-analysis. Journal of Infection.

LEUSIN, Fabiane. Farmacocinética do Meropenem infundido por 3 horas em pacientes criticamente enfermos em terapia renal substitutiva contínua. 2012.

MENDES, N. S., COSTA, M. L. D. ., MIGUEL, R. B. ., CHICA, J. E. L., PAULINO, T. D. P. AGOSTINHO, F. ., RODRIGUES, W. F. ., & MIGUEL, C. B. (2020). USO DE LINEZOLIDA NA TERAPIA MEDICAMENTOSA CONTRA BACTÉRIAS MULTIRRESISTENTES. REVISTA SAÚDE ULTIDISCIPLINAR, 4(1). recuperado de http://revistas.famp.edu.br/revistasaudemultidisciplinar/article/view/60

MIN, J. Y & JANG, Y. J. (2012). Macrolide therapy in respiratory viral infections. Mediators of inflammation, 2012.

MINISTÉRIO DA SAÚDE. Diretrizes para diagnóstico e tratamento da Covid-19 2020. Disponível em https://www.rs.gov.br//

MORO, Luiza Carolina. Perfil epidemiológico dos casos hospitalizados por COVID-19 na 11ª Coordenadoria Regional de Saúde. 2021.

OPATOWSKIi, M.,BRUN-BUISSON, C., TOUAT, M., SALOMON, J., GUILLEMOTT,D.,TUPPIN, P., & WATIER, L. (2021). Antibiotic prescriptions and risk factors for antimicrobial resistance in patients hospitalized with urinary tract infection: a matched case-control study using the French health insurance database (SNDS).

ORGANIZATION, World Health. Anatomical Therapeutic Chemical Classification. Geneva: World Health Organization,, 2019. Disponível em:

https://www.who.int/tools/atc-ddd-toolkit/atc-classification#:~:text=In%20the%20Anatomical%20Therapeutic%20Chemical,groups%20at%20five%20different%20levels.

O'TOOLE, Ronan F. The interface between COVID-19 and bacterial healthcare associated infections. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases vol. 27,12 (2021): 1772-1776. doi:10.1016/j.cmi.2021.06.001

PANIZ-MONDOLFI, A. et al. Central Nervous System Involvement by Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2). Journal of Medical Virology, p. jmv.25915, 21 abr. 2020.

RAWSON, T. M., MOORE, L. S., ZHU, N., RANGANATHAN, N., SKOLIMOWSKA, K.,

GILCHRIST, M & HOLMES, A. (2020). Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing. Clinical Infectious Diseases.

RICE LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis. 2008;197(8):1079–81. https://doi.org/10.1086/533452

RODRIGUES, Luana Kamila Castilho et al. Perfil bacteriano de pacientes admitidos em unidade de terapia intensiva do centro de medicina tropical de rondônia durante a pandemia do COVID‐19. The Brazilian Journal Of Infectious Diseases, [S.L.], v. 25, p. 1-1, jan. 2021. Elsevier BV. http://dx.doi.org/10.1016/j.bjid.2020.101428.

SAURESSIG, Milena Albrech.,RAUBER, Sara Cristina;BOTELHO,Thayná Ellen. Infecção secundária bacteriana em pacientes com covid-19 grave internados em unidade de tratamento intensivo. Trabalho de conclusão de curso. Graduação em Biomedicina, Várzea Grande, 2021.

SILVA DAVID., MARIA TEREZA SANTOS. O impacto do uso indiscriminado de antibioticos na pandemia do COVID-19. PANDEMIA: Caminhos para Aprendizagem.[S. l.]: Pedro & João Editores, p. 165, 2021.

SILVA TFA, et al. Mecanismo de ação, efeitos farmacológicos e reações adversas da ceftriaxona: Uma revisão de Literatura. Revista Eletrônica de Farmácia. Vol. XI (3) 48–57, 2014.

SOUZA FC, Baroni MMF e Roese FM. Perfil de utilização de antimicrobianos na unidade de terapia intensiva de um hospital público. Rev. Bras. Farm. Hosp. Serv. Saúde, 8(4): 37-44, 2018.Doi: 10.30968/rbfhss.2017.084.007

WORLD HEALTH ORGANIZATION. Report of the WHO-China joint mission on coronavirus disease 2019 (Covid-19). Genebra: WHO, 20 fev. 2020. Disponível em:

<https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on- covid-19-final-report.pdf> Acesso em: 10 mai 2022.

WORLD HEALTH ORGANIZATION. WHO Coronavirus Disease (Covid-19) Dashboard. Genebra:

WHO, 2020. Disponível em: <https://covid19.who.int>. Acesso em: 10 mai 2022.

UZUNIAN, A. Coronavirus SARS-CoV-2 and Covid-19. Jornal Brasileiro de PatologiaeMedicinaLaboratorial,56(4).Disponívelem:<https://www.scielo.br/j/jbpml/a/ Hj6QN7mmmKC4Q9SNNt7xRhf/?format=pdf&lang=pt> acessado em: 10 maio 2022.

ZEITOUN, Sandra Salloum et al. Incidência de pneumonia associada à ventilação mecânica em pacientes submetidos à aspiração endotraqueal pelos sistemas aberto e fechado: estudo prospectivo-dados preliminares. Revista Latino-americana de enfermagem, v. 9, n. 1, p. 46-52, 2001.

Downloads

Published

2023-10-09

How to Cite

CORREIA BAUMGARTNER, A.; KAEFER, F.; KELLY SABEC PEREIRA, D. A A resistência bacteriana à antimicrobianos na pandemia da covid-19: Bacterial resistance to antimicrobials the covid-19 pandemic. Extensão em Foco (ISSN: 2317-9791), [S. l.], v. 11, n. 1, p. 32–49, 2023. DOI: 10.33362/ext.v11i1.3170. Disponível em: https://periodicos.uniarp.edu.br/index.php/extensao/article/view/3170. Acesso em: 12 may. 2024.

Issue

v. 11 n. 1 (2023)

Section

Artigos

License

Copyright (c) 2023 Extensão em Foco (ISSN: 2317-9791)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Autores que publicam nesta revista concordam com os seguintes termos:

    1. Autores mantém os direitos autorais e concedem à revista o direito de primeira publicação, com o trabalho simultaneamente licenciado sob a Licença Creative Commons Attribution que permite o compartilhamento do trabalho com reconhecimento da autoria e publicação inicial nesta revista.

    1. Autores têm autorização para assumir contratos adicionais separadamente, para distribuição não-exclusiva da versão do trabalho publicada nesta revista (ex.: publicar em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial nesta revista.

  1. Autores têm permissão e são estimulados a publicar e distribuir seu trabalho online (ex.: em repositórios institucionais ou na sua página pessoal) a qualquer ponto antes ou durante o processo editorial, já que isso pode gerar alterações produtivas, bem como aumentar o impacto e a citação do trabalho publicado (Veja O Efeito do Acesso Livre).